TNFRSF8 and classic Hodgkin lymphoma: Brentuximab vedotin is currently approved as a monotherapy for adult patients with R/R CD30-positive cHL following ASCT or following ≥ 2 prior therapies when ASCT or multi-agent chemotherapy is not a treatment option [44].